Responding to the Trump administration’s drug pricing proposals, the ACR released a set of principles it hopes will help guide any drug policy changes.1 The principles underscore what is critically needed for rheumatologists to provide the best and safest care to their patients, many of whom require ongoing treatment for chronic conditions. “The ACR has…
Search results for: pharmacy benefit managers
AMA House of Delegates 2018 Annual Meeting Recap
On June 8–13, the AMA House of Delegates (HOD) came together in Chicago for its 2018 Annual Meeting. With the recent change in apportionment of geographic and specialty delegates now equal to each other, more than 600 members of the HOD were present, with several hundred staff and attendees from the AMA and other medical…
The ACR’s Congressional Advocacy Produces Results
The underlying tenet of the ACR’s advocacy efforts is that we cannot effect change for our profession and our patients unless we take our issues directly to decision makers. As I write this column, I am highly encouraged by the progress we have made so far this year in the advocacy realm. At the same…
ACR’s Affiliate Society Council Reports Solid Gains in Advocacy Efforts
It’s May, and soon, most state legislatures will be adjourning for the remainder of the year. Joseph Cantrell, JD, senior manager of state affairs for the ACR, who tracks the progress of state and federal patient care legislation, reports that several states saw solid gains during 2018 state sessions, which typically run from January to…
Trump Says Drug Companies to Announce “Massive” Price Cuts Soon
WASHINGTON (Reuters)—President Donald Trump on Wednesday said he expects major drug companies to slash prices on their products in two weeks, but did not provide details on which companies would do so or how such reductions would be made. Health care lobbyists in Washington said they were caught by surprise and had no idea what…
ACR/ARHP Members Call on Congress to Restore Patients’ Voices
WASHINGTON, D.C.—The ACR hosted the 2018 Advocacy Leadership Conference in Washington, D.C., on May 16–17. Rheumatology professionals from around the country flew to our nation’s capitol to attend the conference, where advocates heard from key policymakers and spoke with lawmakers about the issues that affect the rheumatology community—and what ACR/ARHP members can do to influence policy….
Forging Alliances Proves Successful for West Virginia Society
With only 15 practicing rheumatologists in the state, members of West Virginia’s Rheumatology (WVR) Society knew early on they needed a stronger voice to help their patients. So WVR Society President Suzanne Gharib, MD, joined West Virginia’s state medical society, comprising physicians from a range of specialties. “It turns out our state medical society was…
Generic-Drug Price Fixing: Is It Happening?
It started with an inhaler. Like many of you, I am a rheumatologist. And like you, I see some patients more often their own primary care provider. This is so often the case that I have gradually devolved into their backup, all-purpose doctor. I am the doc they notify when they get hospitalized for pneumonia…
Arkansas PBM Bill: A Step in the Right Direction
During a three-day special legislative session in March, Arkansas Governor Asa Hutchinson (R) signed into law the first bill in the U.S. intended to address a lack of transparency among pharmacy benefit managers (PBMs) and their role in the high cost of prescription drugs.1 The bill, H.B. 1010: Arkansas Pharmacy Benefits Manager Licensure Act, will…
FDA’s Gottlieb Eyes PBM Consolidation Impact on Generic Entry: CNBC
NEW YORK (Reuters)—The head of the U.S. Food & Drug Administration Scott Gottlieb said on Wednesday that he was concerned about the impact of deals like the CVS Health purchase of Aetna Inc. on the ability of pharmaceutical companies to block the entry of cheaper copycat drugs. As the pharmacy benefit managers and the drug…
- « Previous Page
- 1
- …
- 8
- 9
- 10
- 11
- 12
- …
- 16
- Next Page »